15 October 2021 - Merck and Eisai today announced that the CHMP of the EMA has adopted positive opinions recommending approval of the combination of Keytruda and Lenvima (marketed as Kisplyx in the European Union for the treatment of advanced renal cell carcinoma), the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, for two different indications.

One positive opinion is for the first-line treatment of adult patients with advanced renal cell carcinoma, and the other is for the treatment of adult patients with advanced or recurrent endometrial carcinoma who have disease progression on or following prior treatment with a platinum-containing therapy in any setting and are not candidates for curative surgery or radiation.

Read Merck press release